BACKGROUND AND OBJECTIVES: Hyperuricemia is associated with hypertension, inflammation, renal disease progression, and cardiovascular disease. However, no data are available regarding the effect of allopurinol in patients with chronic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, randomized trial of 113 patients with estimated GFR (eGFR) <60 ml/min. Patients were randomly assigned to treatment with allopurinol 100 mg/d (n = 57) or to continue the usual therapy (n = 56). Clinical, biochemical, and inflammatory parameters were measured at baseline and at 6, 12, and 24 months of treatment. The objectives of study were: (1) renal disease progression; (2) cardiovascular events; and (3) hospitalizations of any causes. RESULTS:Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. In the control group, eGFR decreased 3.3 +/- 1.2 ml/min per 1.73 m(2), and in the allopurinol group, eGFR increased 1.3 +/- 1.3 ml/min per 1.73 m(2) after 24 months. Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. After a mean follow-up time of 23.4 +/- 7.8 months, 22 patients suffered a cardiovascular event. Diabetes mellitus, previous coronary heart disease, and C-reactive protein levels increased cardiovascular risk. Allopurinol treatment reduces risk of cardiovascular events in 71% compared with standard therapy. CONCLUSIONS:Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol reduces cardiovascular and hospitalization risk in these subjects.
RCT Entities:
BACKGROUND AND OBJECTIVES:Hyperuricemia is associated with hypertension, inflammation, renal disease progression, and cardiovascular disease. However, no data are available regarding the effect of allopurinol in patients with chronic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, randomized trial of 113 patients with estimated GFR (eGFR) <60 ml/min. Patients were randomly assigned to treatment with allopurinol 100 mg/d (n = 57) or to continue the usual therapy (n = 56). Clinical, biochemical, and inflammatory parameters were measured at baseline and at 6, 12, and 24 months of treatment. The objectives of study were: (1) renal disease progression; (2) cardiovascular events; and (3) hospitalizations of any causes. RESULTS: Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. In the control group, eGFR decreased 3.3 +/- 1.2 ml/min per 1.73 m(2), and in the allopurinol group, eGFR increased 1.3 +/- 1.3 ml/min per 1.73 m(2) after 24 months. Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. After a mean follow-up time of 23.4 +/- 7.8 months, 22 patients suffered a cardiovascular event. Diabetes mellitus, previous coronary heart disease, and C-reactive protein levels increased cardiovascular risk. Allopurinol treatment reduces risk of cardiovascular events in 71% compared with standard therapy. CONCLUSIONS:Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol reduces cardiovascular and hospitalization risk in these subjects.
Authors: Mohamed E Suliman; Richard J Johnson; Elvia García-López; A Rashid Qureshi; Hadi Molinaei; Juan Jesús Carrero; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Bengt Lindholm; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-11 Impact factor: 8.860
Authors: Uday M Khosla; Sergey Zharikov; Jennifer L Finch; Takahiko Nakagawa; Carlos Roncal; Wei Mu; Karina Krotova; Edward R Block; Sharma Prabhakar; Richard J Johnson Journal: Kidney Int Date: 2005-05 Impact factor: 10.612
Authors: Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Magdalena Madero; Mark J Sarnak; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Andrew S Levey; Vandana Menon Journal: Am J Kidney Dis Date: 2009-03-20 Impact factor: 8.860
Authors: Daria B Crittenden; R Aaron Lehmann; Laura Schneck; Robert T Keenan; Binita Shah; Jeffrey D Greenberg; Bruce N Cronstein; Steven P Sedlis; Michael H Pillinger Journal: J Rheumatol Date: 2012-06-01 Impact factor: 4.666
Authors: Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay Journal: J Sex Med Date: 2013-09-25 Impact factor: 3.802
Authors: Ali Bakan; Alihan Oral; Omer Celal Elcioglu; Mumtaz Takir; Osman Kostek; Abdullah Ozkok; Semih Basci; Abdullah Sumnu; Savas Ozturk; Murat Sipahioglu; Aydın Turkmen; Luminita Voroneanu; Adrian Covic; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2015-03-12 Impact factor: 2.370